StemCell Therapy

TORONTO, May 1, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, California.

"We are pleased to be a contributor to this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies.

The conference will run from May 1-3, 2017. Please stop by and visit us at booth 316.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit http://www.sqidiagnostics.com.

Contacts:

Sales and Marketing Contact: Russ Peloquin Vice President, Global Commercial Operations 913.484.9022 rpeloquin@sqidiagnostics.com

Investor Relations Contact: Andrew Morris Chief Executive Officer 416.674.9500 ext. 229 amorris@sqidiagnostics.com

Forward-looking Information

This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The forward-looking statements in this news release include without limitation, statements with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at http://www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Read More

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The rest is here:
SQI Diagnostics to Exhibit at the National Biotechnology Conference - Yahoo Finance

[Editors note: Tess Doezema is a doctoral student at the School for the Future of Innovation in Society at Arizona State University, where she researches biotechnology promise and politics.]

[S]cientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance.

Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

Originally posted here:
Are you 'anti-science' if you resist biotechnology on political or economic grounds? - Genetic Literacy Project

The Newburgh Press

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... StockNewsUnion Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ... Traders are Following Technical Levels for Prana Biotechnology Ltd (PRAN)Rives Journal Does Prana Biotechnology Limited (PRAN)'s current closing price competes the market?TopChronicle Notable Institutional Stake In These Stocks: Prana Biotechnology (NASDAQ:PRAN), Adamis Pharmaceuticals ...Wallstreet Investorplace TRA -The Newburgh Press -Is stories all 13 news articles »

See the original post here:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion

USA Commerce Daily

379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... The Cerbat Gem Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F ... Should You Buy, Sell, Or Hold? - Puma Biotechnology, Inc. (PBYI), SkyWest, Inc. (SKYW)USA Commerce Daily Emerald Mutual Fund Advisers Trust Takes Position in Puma ...BBNS Puma Biotechnology (PBYI) Getting Somewhat Negative Press ...Chaffey Breeze HugoPress -Rives Journal -W News all 17 news articles »

More:
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... - The Cerbat Gem

Advances in science, many of them from scientists at USDA or through research funded by USDA, have opened up new options for farmers responding to market needs and environmental challenges. Many new plant varieties being developed or grown by farmers have been produced using genetic engineering, which involves manipulating the plant's genes through techniques of modern molecular biology often referred to as recombinant DNA technology. These techniques are included in what is often referred to as "biotechnology" or "modern biotechnology."

USDA supports the safe and appropriate use of science and technology, including biotechnology, to help meet agricultural challenges and consumer needs of the 21st century. USDA plays a key role in assuring that biotechnology plants and products derived from these plants are safe to be grown and used in the United States. Once these plants and products enter commerce, USDA supports bringing these and other products to the worldwide marketplace.

Three federal agencies are involved in ensuring that plants produced using biotechnology and the many products derived from them are safe for farmers to use, safe to consume as food or feed, and safe for the environment. These are USDA's Animal and Plant Health Inspection Service, the Department of Health and Human Services' Food and Drug Administration, and the United States Environmental Protection Agency. The three agencies regulate these products based on the characteristics of the actual products and their intended uses, and they operate under the existing laws passed by Congress to ensure the safety of plants used in agriculture, the safety of pesticides used in agriculture, and the safety of foods we eat and feeds given to animals. Many other USDA agencies have roles in the development, use, and marketing of these products as well.

Learn more about How the U.S. Government Regulates Biotech Plants.

Since the first successful commercialization of a biotechnology-derived crop in the 1990s, many new crop varieties have been developed and made available to U.S. farmers and farmers worldwide. U.S. farmers have rapidly adopted many of these new GE varieties, so that in 2012, 88 percent of the corn, 94 percent of the cotton, and 93 percent of the soybeans planted in the U.S. were varieties produced through genetic engineering. A large proportion of the production of other crops, such as alfalfa, and papaya, and sugar beet, is also biotech-derived.

Read more about the reasons behind this trend and about how farming practices and the marketplace have changed on USDA's Economic Research Service Biotechnology page.

The United States is the largest exporter of agricultural products, which helps feed the world's population, and our export markets are critical to the health of U.S. farm communities around the country. Most of the corn and soybeans we export are biotechnology-derived, and this means that working with our trading partners is critical to help them understand the technical aspects of new products and how we have determined that they meet our high safety standards, to open up new markets, and to ensure that our products are treated fairly in the global marketplace.

The increasing use of biotechnology in agriculture has changed, and will continue to change, farming and the work of USDA in the long-term. To help understand and address these changes, USDA established the Advisory Committee on Biotechnology and 21st Century Agriculture (AC21). One critical area where the committee has focused its attention is how farmers who produce different crops intended for different customers-biotechnology-derived, conventional, or organic-can best co-exist and produce the crops that meet their customers' needs. The AC21 has provided a report to USDA, with recommendations, on this subject.

Visit the AC21 page to learn more.

See the rest here:
Biotechnology | USDA

Post Analyst

Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$2.08 Per Share The Cerbat Gem Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.08) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Puma ... Focusing the Lens on Puma Biotechnology, Inc. (NASDAQ:PBYI)Rives Journal Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI)HugoPress Brokerage Firm Analysts Consensus on Puma Biotechnology, Inc. (NYSE:PBYI) SharpSpring, Inc. (NASDAQ:SHSP)Midway Monitor Concord Register -Post Analyst -The USA Commerce all 8 news articles »

Link:
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$2.08 Per Share - The Cerbat Gem

By Isabella Zhong

Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on Chinas rising demand for healthcare.

The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, a hormone used in the treatment of platelet deficiencies.

While YSP and TPIAO are expected to deliver strong sales growth in coming years, a recent price cut for anemia drug EPIAO and limited R&D upside in the near term could weigh on 3SBio. Jefferies analyst Eugene Huang initiated coverage of the stock today with a hold rating and an HKD11.50 a share target price, which implies 11% upside.

Huang has more on 3SBios drugs pipeline:

3SBios HER2 (breast cancer) and CD20 (lymphoma) candidates were withdrawn, leaving peers like Fosun potentially to become FTM generics. Besides, we factored in Rmb20/50/110m 17/18/19E sales from Bydureon (exenatide ER, GLP-1, diabetes), which is pending NDA approval. We are concerned there might be a lack of synergy between 3SBio and AstraZenecas diabetes team as well as integration risks.

Shares of 3SBio are up 37% this year and trade at 23 times forward earnings, which is in line with its five year average. Analysts surveyed by FactSet expect 3SBio to grow earnings at a 28.3% average annual pace over the next three to five years. While the stocks scarcity value and long-term growth potential look appealing, investors may want to wait for a better entry point.

View original post here:
3SBio: Is this Chinese Biotechnology Stock a Buy? - Barron's (blog)

FinSMEs (blog)

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M FinSMEs (blog) Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

Follow this link:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

Markets Daily

7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo David R. Rahn & Associates Inc. acquired a new position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent filing with the Securities and Exchange ... Oakwood Capital Management LLC CA Sells 200 Shares of iShares ...Markets Daily Parsec Financial Management Inc. Buys 4115 Shares of iShares NASDAQ Biotechnology Index (IBB)BBNS iShares NASDAQ Biotechnology Index (IBB) Downgraded to "Hold" at Vetr Inc.Transcript Daily Sherwood Daily -Sports Perspectives -Chaffey Breeze all 15 news articles »

Link:
7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. - The Cerbat Gem

Staff Reporter

Islamabad

Minister for National Food Security and Research Sikandar Hayat Khan Bosan called for establishing Islamic biotechnology center in order to develop the agriculture and related sectors for the socio-economic prosperity of Muslim countries. Addressing the 3rd International Conference on Agriculture, Food Security and Biotechnology on an other day, he said that government believes that practical collaboration among the Muslim countries in the cutting edge areas of modern biotechnology was the need of time. The event was organized by Pakistan Agricultural Research Council (PARC) in collaboration with COMSATS, Islamic Educational, Scientific and Cultural Organization (ISESCO) and CIMMYT. The aim of the conference was to share the international best practices of using the biotechnology for the development of agriculture sector and food security. The minister termed the exchange of eminent scientist for short term and graduating students among Islamic countries as another good form of cooperation. He called upon the scientists for encouraging and promoting smart agricultural practices to build the resilience in agri-sector. Pakistan was working on the development of infrastructure for using modern and innovative technologies including the biotechnology for uplift of agriculture, health and industrial sectors of the country, he added. Pakistan has improved its crop yield and productivity over the years and it was producing surplus of wheat, maize, potato and sugarcane, he added. He said that scientist and biotechnologist in Pakistan has achieved the diversification in seed development and moved to a higher value added seeds, particularly in the crops sector. The minister said that all the modern techniques should be replicated after tailor-made alterations keeping in view of local settings and environmental factors.

See the article here:
Bosan for establishing Islamic Biotechnology Centre - Pakistan Observer

LONDON, UNITED KINGDOM--(Marketwired - Apr 28, 2017) - Planda Biotechnology, Inc. ( OTC PINK : PLPL ) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Planda.

Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past 18 years. He was he was with NutraGenesis for 3.5 years, and has recently, before Planda, been working as an independent sales representative for numerous worldwide companies.Since 2016, Mr. Jones has overseen all North American sales efforts for Planda.As the new head of sales and marketing, his responsibilities will expand to overseeing all global sales efforts, working with the company's independent sales reps and distributors, building additional sales channels, and growing the Phytofare brand.

Callum Cottrell-Duffield, President of Planda, commented, "Having worked with Ezra for the past year, I have been impressed with his passion for the product and knowledge of the industry.He has been instrumental in opening our largest accounts and is a driven salesman.As we now expand into a global brand and introduce new products in the coming year, Ezra's experience in building and training a sales force will be invaluable."

About Planda Biotechnology, Inc.

Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing green tea on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Read more here:
Plandai Biotechnology Names Ezra Jones as Vice President of Sales and Marketing - Yahoo Finance

Use of cell imaging technology enables cutting-edge research into the assessment of bioactive compounds in cell lines

Matis is a leading food and biotechnology research institute in Iceland. Matis vision is to increase the value of food processing and food production, and to ensure the safety and quality of food and food products. SelectScience spoke to Dr. Eva Kuttner, to learn more about the technology the company is using in its research.

SS: Could you briefly introduce yourself and your place of work?

EK: My name is Dr. Eva Kuttner, Im a Project Leader in the Analysis and Structure division at Matis (mat=food + is=Iceland). Matis is a government owned, non-profit, independent research company in Iceland. The main focus of Matis is research and development, aligned to the food and biotechnology industries, as well as providing Iceland's leading food analytical testing service for public and private authorities.

I personally am German, and I hold a Diploma (equal to an MSc) in Botany, from the Universitt Braunschweig in Germany. I received my PhD in Integrative Biology (2007-2012) from the University of Guelph (Ontario, Canada).

SS: Could you describe your job role and work at Matis?

EK: My job title is Regional Manager, which means I am responsible for the 2 locations of Matis in the North of Iceland, Saurkrkur and Akureyri. My main work is that of a project leader (bioactives) in the Analysis and Structure Division and I am specialized in screening for bioactive secondary metabolites using in vitro chemical and cell-based assays.

Our laboratory focus is on identifying and describing compounds regarding antioxidant activity for healthcare (anti-diabetes, anti-inflammatory) and skin care. We now have a fully equipped cell laboratory (currently working with two cell lines), and we routinely run chemical and cell-based assays to identify and describe the bioactivity properties of extracted and fractionated compounds.

Testing putative therapeutics

SS: Please tell us about your marine compounds project that you are working on, and the main challenges involved?

EK: We are currently looking into how marine compounds influence the mineralization in a murine chondrocyte cell line (ATDC5). The aim of the project is to test putative therapeutics, to improve joint health. Specifically, we are interested in seeing how they affect differentiation of these cells.

SS: Which methods do you use to investigate this project and how does the BioTek Cytation 5 play a part in this?

EK: We are exposing the cells to different concentrations of fractionated marine compounds in a 96-well microplate format. After 24 days of incubation we stain the cells both with calcein and Alizarin Red to quantify calcium deposition. This is when the Cytation 5 from BioTek comes in: we have a workflow set up that images (magnification 4x) each well in phase contrast and fluorescence (we are using a GFP filter cube for this assay), and also carries out a read of the fluorescence signal. We then perform the Alizarin Red staining, take more pictures and extract the bound color after several washing steps. A further reading step quantifies the Alizarin Red using an absorbance read.

The figure below shows an example read of the calcein stain: first picture, phase contrast, second picture, fluorescence channel (GFP filter cube) and the third picture, overlay of both:

Image courtesy of Dr. Eva Kuttner

SS: What are your main research findings so far?

EK: We have identified several possible inhibitors of mineralization, but we are still in the process of improving the assay protocol to make the quantification of the mineralization more reproducible. The Alizarin Red stain has proven to represent more accurate calcium deposition into the cells, when testing the assay protocol using standard inhibitors like levamisole, so we are using the calcein stain to visualize mineralization, and Alizarin Red to quantify.

SS: What is the future of your research?

EK: We are looking into setting up assays investigating blood pressure. Our project partner developed a product line based on fish protein hydrolysate using trimmings from cod (Gadus morhua). The proteins are extracted and broken down to smaller peptides that have been shown to inhibit a key enzyme involved in increasing blood pressure (ACE). For this research we will develop and perform cell-based assays.

Read more:
Improving Joint Health with Putative Therapeutics at Matis, Iceland's ... - SelectScience

iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at ... The Cerbat Gem Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research note issued to investors on ... iShares NASDAQ Biotechnology Index (IBB) Downgraded to "Hold" at Vetr Inc.Transcript Daily iShares NASDAQ Biotechnology Index (IBB) Stake Raised by Mycio ...Sports Perspectives iShares NASDAQ Biotechnology Index (IBB) Earns Daily Coverage Optimism Score of 0.30Chaffey Breeze BBNS -Petro Global News 24 all 8 news articles »

More:
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at ... - The Cerbat Gem

WEST LAFAYETTE, Ind., April 26, 2017 /PRNewswire/ --SSCI, a division of Albany Molecular Research Inc. (AMRI), has been recognized by Global Health & Pharma (GHP) magazine as the winner of the 2017 Biotechnology Award for Best Global Research & Manufacturing Company in the United States.

"I am truly honored to accept this award on behalf of our dedicated team that is deeply committed to the mission of helping our clients achieve their product development goals and generate valuable intellectual property day in and day out," said David A. Engers, Ph.D., general manager at SSCI. "We are grateful to GHP for recognizing our commitment to client service and data integrity in order to provide unmatched value to the industries we have served for more than a quarter century."

GHP magazine recognizes that the biotechnology industry is increasingly viewed as being the frontline of medical science, and as this movement continues to gain momentum the publication is committed to following the most game-changing advances and revolutionary developments that will form the healthcare world for years to come.

Nathan Angell, GHP awards coordinator, expressed pride in every one of the award winners, "This award recognizes the hard work and dedication of the firms, such as SSCI, and the individuals behind them, that are driving innovation in this vital market. It has been my honor to recognize these dedicated professionals and I would like to wish them the very best of fortunes for the future."

About SSCIAMRI SSCI, LLC (SSCI), a division of AMRI, provides industry leading contract solid-state and analytical testing services and exists to help companies in the pharmaceutical, food, agrochemical, and other chemical industries develop better products and get them to market more quickly. SSCI provides comprehensive cGMP research and analytical services in the characterization and chemistry of solid materials, with particular expertise in small and large molecules being investigated for pharmaceutical use.To learn more about SSCI's solid-state and analytical chemistry services and capabilities,please contact 1-800-375-2179 | http://www.ssci-inc.com.

About GHP MagazineGlobal Health and Pharma (GHP) magazine is a global, information-sharing platform and a multi-disciplinary members community. The publication was established to enhance communication networks and collaboration across all themes and disciplines within three main categories; Human, Animal and Environmental Health.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ssci-receives-a-2017-biotechnology-award-for-global-research-and-manufacturing-300445541.html

The rest is here:
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing - Yahoo Finance

250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank The Cerbat Gem Puma Biotechnology logo Norges Bank acquired a new position in Puma Biotechnology Inc (NYSE:PBYI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 250,598 shares of the biopharmaceutical ... -$2.08 EPS Expected for Puma Biotechnology Inc (PBYI) This QuarterSports Perspectives Analyst Observation On 2 Stocks: Delta Technology (DELT), Puma Biotechnology (PBYI)Post Analyst all 4 news articles »

Excerpt from:
250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank - The Cerbat Gem

Around 130 national and international academicians and scientists hailing from seven different countries including Turkey, Tunisia, Sudan, Iran, Sri Lanka, and Uzbekistan attended a workshop held here to promote the safe use of modern biotechnology to attain the goal of food security and defeating hunger and poverty.

Minister for Food Security and Research Sikandar Hayat Khan Bosan inaugurated the 3rd International Conference on Agriculture, Food Security and Biotechnology on Wednesday.

The 2-day event being held at the National Agriculture Research Center, Islamabad, is jointly organised by Commission on Science and Technology for Sustainable Development in the South (COMSATS), ISESCO and Pakistan Agricultural Research Council (PARC).

Addressing the audiences, the minister said that it was time that the countries of the region should encourage and support smart agricultural practices.

He said safe use of modern biotechnology was needed to enhance agricultural production and get rid of malnutrition and starvation. The minister pledged full support for agricultural production which was the backbone of economy with sustainable food security.

Dr Ghulam Muhammad Ali, Member Coordination and Monitoring, PARC, Islamabad, noted that advances in science and technology were the need of time for food security and safety. Noting the hunger still prevailing in various parts of the world, he opined that biotechnology was the basis of production of vast variety of transgenic and genetically modified crops which can solve the problem of hunger.

He said that the conference having similar agenda was good for the developing countries as it would open ways for research, collaboration and capacity building.

Speaking on the occasion, Dr Kauser Malik, Department of Biological Sciences, FC College Lahore, mentioned that it was our fear of unknown that kept the human beings away from adapting new technologies and advocated the use of genetically modified crops for addressing hunger.

In his message, Dr SM Junaid Zaidi, Executive Director COMSATS, said that despite major developments around the globe, many areas struggle with challenges of starvation and malnutrition. Even the developed countries cannot engage in bigger pursuits without ensuring food security. Mentioning the importance of biotechnology in agriculture, he noted that biotechnological influence on food production and agriculture is undeniable especially for countries like Pakistan with fertile lands and good weather conditions.

The message from Director General ISESCO, HE Dr. Abdulaziz Othman Altwaijri, noted that there was a dire need to provide an enriching and engaging environment to foster crop science research towards new and improved livelihood opportunities and sustainable food security. He considered collaborations in this regard necessary and appreciated the cooperation between ISESCO and COMSATS.

Shields were given to the esteemed participants who came from different countries for the conference.

See the original post:
Use of biotechnology must to attain food security: Bosan | Pakistan ... - Pakistan Today

3D Systems has announced a bioprinting agreement with United Therapeutics which will see the two companies develop solid-organ scaffolds for human transplants with 3D printing.

Combining their respective expertise in 3D printing and regenerative medicine and organ manufacturing, the collaboration will remain for a number of years.

The agreement will pit 3D Systems personnel alongside professionals from a United Therapeutics subsidiary, Lung Biotechnology PBC. Since the collaboration will primarily focus on the development of 3D printing systems for solid-organ lung scaffolds, Lung Biotechnology PBC is seen as best placed to work with 3D Systems.

The printing system will target collagen, and other building block proteins, as scaffold raw materials. Lung Biotechnology PBC will cellularize the scaffolds with patient-specific biological material, including re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs, said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation.

3D Systems is a company with a wealth of experience in the medical sector. Its precision healthcare capabilities include simulation, virtual surgical planning, and the printing of medical and dental devices. Two of 3D Systems leading executives are not only confident in their companys own knowledge of the medical 3D printing sector, but also of United Therapeutics own expertise. Though conceding the challenge is not straight forward, the pair foresee new solutions being born from the partnership.

As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting, said Vyomesh Joshi, Chief Executive Officer, 3D Systems. We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the calibre of United Therapeutics to provide healthcare solutions of the future.

Chuck Hull, Executive Vice President, Chief Technology Officer, 3D Systems, added: Combining the resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge. This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC.

Meanwhile, the collaboration and joint development will add another technology alternative to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr Rothblatt concludes: Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care program. Indeed, we expect one personalised organ transplant will avoid years of health care spending on palliative medical therapies.

Go here to see the original:
3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants - TCT Magazine

No matter how many times I read or write about it, I am still overwhelmed and amazed when I see what 3D printing technology is currently able to do for the medical field, and what it has the potential to do down the line. Today, 3D Systems, a company thats nearly synonymous with precision healthcare capabilities, and biotechnology company United Therapeutics Corporation announced a joint plan to develop solid-organ scaffolds for use in human transplants. The multi-year development and collaboration is a good fit, combining 3D Systemshealthcare and 3D printing expertise with the organ manufacturing and regenerative medicine proficiency of United Therapeutics, which is also a member of the consortium that makes up the Advanced Tissue Biofabrication Manufacturing USA Institute.

Vyomesh Joshi, CEO of 3D Systems, said, As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting.We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the caliber of United Therapeutics to provide healthcare solutions of the future.

In addition to collaborating with United Therapeutics, which is focused on developing and commercializing products that address the medical needs of patients living with chronic and life-threatening conditions, 3D Systems will also work with its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, which is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Through several technologies that expand the supply or delay the need for transplantable organs, Lung Biotechnology PBC addresses head-on the critical shortage of transplantable lungs, and other organs, in the US. Withthe subsidiary also on board with the 3D Systems collaboration, an additional technology alternative can be added to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr. Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics, said, Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care problem.Indeed, we expect one personalized organ transplant will avoid years of health care spending on palliative medical therapies.

The focus of the joint bioprinting agreement is to develop 3D printing systems for solid-organ scaffolds, and with Lung Biotechnology PBCs participation, obviously the first thing the companies will tackle is lung scaffolds. Scaffolds are an important part of the bioprinting process, as they give printed cells, and organs, a structure to develop and grow on. So determining the correct way to create a scaffold is incredibly important to the success of these endeavors.

Combiningthe resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge.This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC, said Chuck Hull, Executive Vice President and Chief Technology Officer for 3D Systems.

The 3D printing system that 3D Systems and United Therapeutics hope to create will be targeting collagen, along with other building block proteins, as the raw materials for the scaffolds themselves. In turn, Lung Biotechnology PBC will then celluralize the scaffolds using patient-specific biological material, which includes re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs.By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation, said Dr. Rothblatt.

[Image: OPTN]

Here is the original post:
3D Systems and United Therapeutics to Develop 3D Printing Biotechnology for Solid-Organ Scaffolds - 3DPrint.com

LONDON--(BUSINESS WIRE)--

Technavio has announced the top five leading vendors in their recent global biotechnology reagents market report. This research report also lists four other prominent vendors that are expected to impact the market during the forecast period.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170425006359/en/

The global biotechnology market is a continuously growing market and has witnessed a speedy growth in past few years. The increase in bio-related technologies, research labs, and centers and commercial requests are the main reasons behind the growth of the global biotechnology reagents market. Increasing investment in R&D of biotechnology, from private and government sector, is the key driver for the growth of the global biotechnology reagents market.

Competitive vendor landscape

According to the report, the global biotechnology reagents market consists of a sizeable number of key global players, along with regional and local players. These players have a vast geographical presence with huge production facilities located, globally. There are a considerable number of small regional vendors with significant shares in the market

The major players compete depending on the innovations, price, and quality of the product. Some players can capture the market due to lower costs compared to their competitors. Also, few suppliers financial, technological, and other resources are better as compared with their competitors who can adapt to the changes in the market demand, says Ajay Adhikari, a lead bio-chemicals and bio-materials research analyst from Technavio.

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Top five biotechnology reagents market vendors

Agilent Technologies

Agilent Technologies is one of the leading companies in the biotechnology reagents market. The company produces control reagents, blocking reagents, buffers, diluents, and lysing, fixation, and permeabilization reagents.

BD

BD is one of the major biotechnology reagents producing companies. The company offers reagents for research, clinical, and custom services. It provides reagents for various applications such as immunoassays, cell-based assays, and clinical research.

Merck

Merck is one of the largest biotechnological reagents manufacturing companies. The company provides a wide range of reagents and solvents for different functions such as DNA and RNA synthesis, in vitro diagnostics, and instrumental inorganic analysis.

Bio-Rad Laboratories

Bio-Rad is one of the key vendors for the biotechnology reagents market. The company provides biotechnology reagents for clinical diagnostics, PCR technology, protein assay, and immunodetection reagents.

Thermo Fisher Scientific

Thermo Fisher Scientific is one of the key vendors in the biotechnology reagents market. The company offer reagents for various applications such as an immunogenic adjuvant, protein gel buffers, nucleic acid gel buffers, flow cytometer buffers and reagents, immunoassay buffers and reagents, protein purification buffers, and diagnostic testing.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as theyre published in addition to all 6,000+ existing reports covering segments like industrial gases, olefins, and metals and minerals. This subscription nets you thousands in savings, while staying connected to Technavios constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006359/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170425006359/en/

See the rest here:
Top 5 Vendors in the Biotechnology Reagents Market From 2017 to 2021: Technavio - Yahoo Finance

April 26, 2017 The authors artwork, illustrating the article, was also featured on the cover of Lab on a Chip. Credit: Royal Society of Chemistry

Scientists in the U.S have a designed a computer game that could help with biomedical research.

Scientists increasingly use miniscule robots to solve a range of problems, from cancer treatment to water purification. And, as with a lot of technology, the race is on to make these devices ever smaller.

However there is a limit to how far you can go with a mechanical device moving parts such as motors can physically only get so small.

So scientists are looking to the natural world to help. Single cell organisms, such as bacteria and algae, could make the parts in the miniaturised robots move, without the need for an external power source.

Such organisms respond to changes in their environment such as light and food by moving, and if these movements can be harnessed, we can use them as motors.

In a new paper just published in Lab on a Chip, Ingmar Riedel-Kruse and fellow scientists from Stanford University in the U.S. have demonstrated the use of one such organism, in the form of a game.

It's based on Euglena gracilis, single cell algae that move in response to changes in strong light. In the game, the organisms are directed around a maze or "captured" in a space on the screen by the users turning lights on and off. The ability to control the movement of the algae demonstrates their potential application in mini, single cell organism-driven motors.

In this set-up, the algae's movements are programmable a promising first step towards creating a microcomputer built on biotechnology.

Explore further: Single cell organism firm joins top ranks of Japan bourse

More information: Amy T. Lam et al. Device and programming abstractions for spatiotemporal control of active micro-particle swarms, Lab Chip (2017). DOI: 10.1039/C7LC00131B

The high-tech titans of Japanese industry were joined Wednesday in the major league of the Tokyo Stock Exchange by a company exploiting the 500-million-year-old science of a single cell organism.

Diatoms are unicellular algae that are native in many waters. They are a major component of marine phytoplankton and the food base for a large variety of marine organisms. In addition, they produce about one fifth of the ...

A new 3-D printed, easily assembled smartphone microscope developed at Stanford University turns microbiology into game time. The device allows kids to play games or make more serious observations with miniature light-seeking ...

Scientists at the John Innes Centre have discovered that Euglena gracilis, the single cell algae which inhabits most garden ponds, has a whole host of new, unclassified genes which can make new forms of carbohydrates and ...

Scientists at the Swedish Museum of Natural History have found fossils of 1.6 billion-year-old probable red algae. The spectacular finds, publishing on 14 March in the open access journal PLOS Biology, indicate that advanced ...

In an algae-eat-algae world, it's the single-celled photosynthetic organisms at the top (layer of the ocean) that absorb the most sunlight. Underneath, in the sublayers, are cryptophyte algae that must compete for photons ...

Being first in a new ecosystem provides major advantages for pioneering species, but the benefits may depend on just how competitive later-arriving species are. That is among the conclusions in a new study testing the importance ...

Giacomo Cavalli's team at the Institute of Human Genetics (University of Montpellier / CNRS), in collaboration with the French National Institute for Agricultural Research (INRA), has demonstrated the existence of transgenerational ...

(Phys.org)A pair of researchers with Harvard and Yale Universities has conducted a study of optimal human throwing techniques and found which work best under which conditions. In their paper published in the journal Royal ...

Biologists at the University of California San Diego have demonstrated for the first time that a widely used pesticide can significantly impair the ability of otherwise healthy honey bees to fly, raising concerns about how ...

Newborn humpback whales and their mothers whisper to each other to escape potential predators, scientists reported Wednesday, revealing the existence of a previously unknown survival technique.

New genes are more likely to appear on the stage of evolution in full-fledged form rather than gradually take shape through successive stages of "proto genes" that become more and more refined over generations. This is the ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more here:
Pac-Man meets biotechnology - Phys.Org